BioNano Genomics Announces Strategic Financial Boost with $10 Million Registered Direct Offering
BioNano Genomics (BNGO) recently announced a strategic move to bolster its financial position through a registered direct offering aimed at raising approximately $10 million before expenses. In this transaction, Bionano Genomics, Inc. plans to sell over 11 million shares alongside warrants to institutional investors. Each share sold will be accompanied by a warrant entitling the holder to purchase additional shares at an exercise price of $0.571 per share.
READ: OAS to Step in as Mediator in Guatemala’s Power Transition Crisis
BioNano
H.C. Wainwright & Co. has been appointed as the exclusive placement agent for this offering, which is expected to close on July 8, 2024, subject to customary closing conditions.
The capital raised from this offering is intended to support BioNano Genomics’ general corporate purposes, including funding ongoing research initiatives and covering capital expenditures essential for advancing its technology and business objectives.
BioNano Genomics specializes in genomic analysis tools, particularly in the field of optical genome mapping. This strategic funding initiative underscores the company’s commitment to strengthening its financial foundation and enhancing its capabilities in genomic research and development.
